TABLE 4.
Network meta‐analysis of secondary outcomes
| Glucose/weight loss | ||||
| BPD | 2.08 (0.58, 3.58) | 0.31 (−0.95, 1.57) | −0.58 (−1.75, 0.58) | −0.22 (−1.43, 0.98) |
| −0.76 (−2.79, 1.28) | LAGB | −0.89 (−1.98, 0.20) | −0.76 (−1.99, 0.48) | −2.31 (−3.16, −1.47) |
| 0.55 (−1.52, 2.63) | 1.31 (−0.20, 2.82) | LSG | 0.14 (−1.00, 1.28) | −1.42 (−2.11, −0.73) |
| 0.41 (−1.36, 2.18) | 1.17 (−0.05, 2.39) | −0.14 (−1.26, 0.98) | RYGBP | −1.56 (−2.46, −0.65) |
| −0.77 (−2.54, 1.01) | −0.01 (−1.19, 1.18) | −1.32 (−2.73, 0.10) | −1.18 (−2.12, −0.23) | NST |
| Systolic/diastolic pressure | ||||
| BPD | −0.08 (−3.33, 3.17) | 0.02 (−3.62, 3.65) | 0.38 (−2.28, 3.04) | −0.82 (−3.47, 1.84) |
| −0.89 (−4.38, 2.59) | LAGB | 0.09 (−3.13, 3.32) | 0.45 (−1.68, 2.58) | −0.74 (−2.72, 1.24) |
| 0.11 (−3.79, 4.00) | 1.00 (−2.46, 4.46) | LSG | 0.36 (−2.26, 2.98) | −0.83 (−3.46, 1.79) |
| 0.51 (−2.34, 3.35) | 1.40 (−0.90, 3.69) | 0.40 (−2.42, 3.21) | RYGBP | −1.19 (−2.41, 0.02) |
| −0.73 (−3.57, 2.12) | 0.17 (−1.96, 2.29) | −0.84 (−3.65, 1.98) | −1.23 (−2.54, 0.07) | NST |
| Total cholesterol/triglycerides | ||||
| BPD | −2.55 (−6.88, 1.78) | −0.13 (−5.42, 5.16) | −0.01 (−3.56, 3.53) | −1.65 (−5.19, 1.89) |
| −1.03 (−3.20, 1.15) | LAGB | 2.42 (−2.46, 7.31) | 2.54 (−0.37, 5.44) | 0.90 (−1.75, 3.55) |
| −1.56 (−4.20, 1.09) | −0.53 (−2.94, 1.88) | LSG | 0.11 (−3.82, 4.04) | −1.53 (−5.83, 2.78) |
| −1.04 (−2.83, 0.76) | −0.01 (−1.45, 1.43) | 0.52 (−1.42, 2.46) | RYGBP | −1.64 (−3.40, 0.13) |
| −1.48 (−3.27, 0.32) | −0.45 (−1.77, 0.87) | 0.08 (−2.05, 2.21) | −0.44 (−1.32, 0.45) | NST |
| HDL‐C/LDL‐C | ||||
| BPD | 0.06 (−2.12, 2.23) | −1.26 (−3.16, 0.64) | −0.98 (−2.56, 0.60) | −1.31 (−2.89, 0.27) |
| 1.75 (−2.08, 5.58) | LAGB | −1.32 (−3.22, 0.58) | −1.04 (−2.62, 0.54) | −1.37 (−2.96, 0.21) |
| −0.77 (−4.56, 3.03) | −2.52 (−5.83, 0.79) | LSG | 0.28 (−0.84, 1.40) | −0.05 (−1.27, 1.17) |
| −1.11 (−4.22, 2.00) | −2.86 (−5.41, −0.32) | −0.34 (−2.65, 1.96) | RYGBP | −0.33 (−1.04, 0.38) |
| 0.82 (−2.29, 3.93) | −0.93 (−3.29, 1.42) | 1.58 (−0.90, 4.07) | 1.93 (0.51, 3.34) | NST |
Note: Comparisons between drugs should be read from left to right. The estimates are located at the crossing between the column‐defining treatment and row‐defining treatment. For mean change of glucose, weight loss, systolic and diastolic pressure, total cholesterol, triglycerides and LDL‐C. An SMD lower than 0.01 favours the column‐defining treatment; for mean change of HDL‐C, an SMD greater than 0.01 favours the column‐defining treatment. The significant results are presented in bold.
Abbreviations: BPD, biliopancreatic diversion without duodenal switch; CrI, credible interval; LAGB, laparoscopic‐adjustable gastric banding; LDL‐C, low‐density lipoprotein cholesterol; LSG, laparoscopic sleeve gastrectomy; HDL‐C, high‐density lipoprotein cholesterol; NST, nonsurgical treatment; RYGBP, Roux‐en‐Y gastric bypass; SMD, standardized mean difference.